Subtype
Gastroesophageal Junction Carcinoma
CI-CAN-00005404Explore in graph →
231 active trials9 approved drugs25 evidence items
- NCIt
- C203675
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005404Explore in graph →
Clinical trials
706 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (86)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03030404 | Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer | completed | — | 733 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT04921904 | Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca | completed | Phase 1 / Phase 2 | 26 | Baylor Research InstituteOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04209686 | Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma | completed | Phase 2 | 19 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07791329 | Sequential FDG-PET and miRNA as Biomarkers of Preoperative Treatment Strategy in LA Oesophago-Gastric Cancer(GastroPET) | completed | Phase 2 | 144 | Masaryk Memorial Cancer InstituteOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT03615326 | Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) | completed | Phase 3 | 738 | Merck Sharp & Dohme LLCINDUSTRY | 20 | Aug 26, 2026 | clinicaltrials |
| NCT01882933 | D2 Resection and HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) in Locally Advanced Gastric Carcinoma(GASTRICHIP) | completed | Phase 3 | 367 | Hospices Civils de LyonOTHER | 2 | Aug 24, 2026 | clinicaltrials |
| NCT07781319 | Early Gastric Cancer in the Spanish EURECCA Registry | completed | — | 600 | Corporacion Parc TauliOTHER | 0 | Aug 24, 2026 | clinicaltrials |
| NCT04522336 | Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer | completed | Phase 1 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT04210115 | Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975) | completed | Phase 3 | 703 | Merck Sharp & Dohme LLCINDUSTRY | 27 | Jul 22, 2026 | clinicaltrials |
| NCT04164979 | Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma | completed | Phase 2 | 34 | University of California, IrvineOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT04739202 | Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)(IMMUNOGAST) | completed | Phase 2 | 54 | Hospices Civils de LyonOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT01196390 | Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer | completed | Phase 3 | 203 | National Cancer Institute (NCI)NIH | 1 | Jun 2, 2026 | clinicaltrials |
| NCT05052801 | Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression(FORTITUDE-101) | completed | Phase 3 | 547 | AmgenINDUSTRY | 37 | May 27, 2026 | clinicaltrials |
| NCT05955833 | 89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study(HER Image) | completed | N/A | 6 | Amsterdam UMC, location VUmcOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT04984733 | Temozolomide + Nivolumab in MGMT Methylated Oesophagogastric Cancer(ELEVATE) | completed | Phase 2 | 13 | University of SouthamptonOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT02606396 | Cryotherapy for Malignant Dysphagia in Patients With Advanced Esophageal Cancer | completed | N/A | 15 | Hunter Holmes Mcguire Veteran Affairs Medical CenterFED | 1 | Apr 14, 2026 | clinicaltrials |
| NCT07529613 | Trastuzumab Deruxtecan Plus Nivolumab Plus Capecitabine Plus Oxaliplatin for HER2 Low Gastric and Gastroesophageal Junction Adenocarcinoma(T-DXd_HER2Low) | completed | Phase 1 / Phase 2 | 30 | National Cancer Center Hospital EastOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT05411133 | Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients | completed | Phase 1 | 33 | Arbele Pty LtdINDUSTRY | 2 | Mar 19, 2026 | clinicaltrials |
| NCT07453433 | Submucosal Pressure Ejection Endoscopic Dissection for Early Gastric Cancer: a Retrospective Cohort Study | completed | — | 548 | Shanghai East HospitalOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT03686488 | TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | completed | Phase 2 | 23 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT03008278 | Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery | completed | Phase 1 / Phase 2 | 51 | National Cancer Institute (NCI)NIH | 1 | Feb 3, 2026 | clinicaltrials |
| NCT01618643 | Aceto-whitening in the Assessment of Gastrointestinal Neoplasia | completed | — | 197 | Portsmouth Hospitals NHS TrustOTHER_GOV | 1 | Dec 24, 2025 | clinicaltrials |
| NCT03246516 | Determinants of Patient Delay in Doctor Consultation in Oeso-gastric Cancers(DELOGAST) | completed | N/A | 258 | University Hospital, LilleOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT05419362 | GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer | completed | Phase 2 | 42 | Genome & CompanyINDUSTRY | 1 | Dec 16, 2025 | clinicaltrials |
| NCT06549816 | A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors | completed | Phase 1 | 6 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 1 | Dec 15, 2025 | clinicaltrials |
| NCT07244471 | Water-injecting Endoscopic Submucosal Dissection for Early Gastric Cancer: a Retrospective Cohort Study | completed | — | 548 | Shanghai East HospitalOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06614439 | PG Versus TG for Advanced PGC | completed | N/A | 96 | National Taiwan University HospitalOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT04208958 | Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer(ConsortiumIO) | completed | Phase 1 / Phase 2 | 56 | Vedanta Biosciences, Inc.INDUSTRY | 1 | Oct 27, 2025 | clinicaltrials |
| NCT04408105 | Survey Study on Barrett's Esophagus Screening(SCREEN-BE) | completed | — | 725 | University of Colorado, DenverOTHER | 1 | Oct 22, 2025 | clinicaltrials |
| NCT05051475 | Endoscopic Radiofrequency Ablation Versus Hybrid Argon Plasma Coagulation in the Treatment of Barrett's Esophagus(RATE) | completed | N/A | 62 | Centre of Postgraduate Medical EducationOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT02738294 | Necessity Assessment of ME-NBI Targeted Biopsy Compared With EFB | completed | N/A | 211 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT04344795 | Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors | completed | Phase 1 | 89 | Tempest TherapeuticsINDUSTRY | 1 | Sep 12, 2025 | clinicaltrials |
| NCT04772989 | A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies(ARC-12) | completed | Phase 1 | 94 | Arcus Biosciences, Inc.INDUSTRY | 3 | Aug 28, 2025 | clinicaltrials |
| NCT02872116 | Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer(CheckMate649) | completed | Phase 3 | 2,031 | Bristol-Myers SquibbINDUSTRY | 29 | Aug 7, 2025 | clinicaltrials |
| NCT02013154 | A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab(P102) | completed | Phase 1 | 151 | Leap Therapeutics, Inc.INDUSTRY | 1 | Aug 3, 2025 | clinicaltrials |
| NCT06030180 | CLUE: CLinical Utility Study of EsoGuard(PR-0410) | completed | N/A | 566 | Lucid Diagnostics, Inc.INDUSTRY | 1 | Jun 27, 2025 | clinicaltrials |
| NCT04082364 | Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer(MAHOGANY) | completed | Phase 2 / Phase 3 | 82 | MacroGenicsINDUSTRY | 9 | Jun 8, 2025 | clinicaltrials |
| NCT04161781 | A Study of PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastroesophageal Junction Cancer | completed | — | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT05524844 | The Microbiome, Bile Acids, and Notch in Barrett's Esophagus (BE) | completed | — | 54 | Columbia UniversityOTHER | 1 | May 11, 2025 | clinicaltrials |
| NCT04032119 | RCT of Gastric ESD With or Without Epineprhine Added Solution | completed | Phase 3 | 800 | Chinese University of Hong KongOTHER | 4 | May 4, 2025 | clinicaltrials |
| NCT03064490 | Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED)(PROCEED) | completed | Phase 2 | 35 | Duke UniversityOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT04014075 | DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02) | completed | Phase 2 | 79 | Daiichi SankyoINDUSTRY | 5 | Apr 3, 2025 | clinicaltrials |
| NCT03123042 | Feasibility Study of Sentinel Navigation Surgery After Non-curative Endoscopic Resection(SENORITA2) | completed | N/A | 243 | National Cancer Center, KoreaOTHER_GOV | 1 | Apr 2, 2025 | clinicaltrials |
| NCT03894618 | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas | completed | Phase 1 | 49 | Shattuck Labs, Inc.INDUSTRY | 4 | Apr 2, 2025 | clinicaltrials |
| NCT03429816 | OPPOSITE: Outcome Prediction of Systemic Treatment in Esophagogastric Carcinoma(OPPOSITE) | completed | N/A | 120 | University Hospital HeidelbergOTHER | 1 | Mar 27, 2025 | clinicaltrials |
| NCT03724851 | Vactosertib in Combination with Pembrolizumab in Metastatic Colorectal or Gastric Cancer | completed | Phase 1 / Phase 2 | 120 | MedPacto, Inc.INDUSTRY | 1 | Mar 25, 2025 | clinicaltrials |
| NCT03195699 | Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers | completed | Phase 1 | 64 | Tvardi Therapeutics, IncorporatedINDUSTRY | 1 | Mar 21, 2025 | clinicaltrials |
Data updated 2 days agoSource updated Sep 28, 2026source: clinicaltrials